Damon Runyon Cancer Research Foundation: FDA Approves Novel Treatment for Acute Myeloid Leukemia
April 16, 2026
April 16, 2026
NEW YORK, April 16 -- The Damon Runyon Cancer Research Foundation issued the following news release on April 14, 2026:
* * *
FDA approves novel treatment for acute myeloid leukemia
Acute myeloid leukemia (AML) is diagnosed in more than 20,000 people in the U.S. each year, and the five-year survival rate remains around 30%. For patients whose disease is driven by mutations in the gene NPM1, the most common mutation in adult AML, treatment options have long b . . .
* * *
FDA approves novel treatment for acute myeloid leukemia
Acute myeloid leukemia (AML) is diagnosed in more than 20,000 people in the U.S. each year, and the five-year survival rate remains around 30%. For patients whose disease is driven by mutations in the gene NPM1, the most common mutation in adult AML, treatment options have long b . . .